This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CLSN Imunon (CLSN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Imunon Stock (NASDAQ:CLSN) 30 days 90 days 365 days Advanced Chart Get Imunon alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.95▼$2.6352-Week Range N/AVolume711 shsAverage Volume150,471 shsMarket Capitalization$13.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Read More… Receive CLSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSN Stock News HeadlinesImunon Inc IMNNMarch 10, 2024 | morningstar.comCLSN.L Regulatory NewsMay 22, 2023 | lse.co.ukTrump’s Bitcoin Reserve is No Accident…For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.May 28, 2025 | Crypto 101 Media (Ad)Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate - Marketscreener.comOctober 9, 2022 | marketscreener.comImunon Reports Partial Results from Ongoing Non-human Primate Study - GlobeNewswireOctober 3, 2022 | globenewswire.comImunon Appoints James E. Dentzer to its Board of Directors - GlobeNewswireOctober 3, 2022 | globenewswire.comImunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) - GlobeNewswireSeptember 29, 2022 | globenewswire.comIMUNON to Present at Chardan's 6th Annual Genetic Medicines - GlobeNewswireSeptember 28, 2022 | globenewswire.comSee More Headlines CLSN Stock Analysis - Frequently Asked Questions How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:CLSN) posted its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative trailing twelve-month return on equity of 50.18% and a negative net margin of 5,229.80%. When did Imunon's stock split? Imunon's stock reverse split before market open on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Acasti Pharma (ACST), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). Company Calendar Last Earnings8/15/2022Today5/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSN CIK749647 Webwww.celsion.com Phone(609) 896-9100Fax609-896-2200Employees27Year Founded1982Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.77 million Net Margins-5,229.80% Pretax Margin-5,506.60% Return on Equity-50.18% Return on Assets-36.94% Debt Debt-to-Equity Ratio0.13 Current Ratio6.52 Quick Ratio6.52 Sales & Book Value Annual Sales$500,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / BookN/AMiscellaneous Outstanding Shares7,099,000Free Float6,768,000Market Cap$13.91 million OptionableOptionable Beta2.27 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:CLSN) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.